Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2017 Earnings Presentation
23 slides from Arcticzymes Technologies Asa's earnings presentation, Apr 27, 2017
Slide 1: Q1 2017 Presentation
Q1 2017 Presentation 27.04.2017, Oslo
Slide 2: Agenda
Agenda • Highlights • Q1 Financials • BetaGlucans • Animal- and Consumer health • Cancer • Advanced wound care • Enzymes • Molecular research and diagnostics • Outlook 2
Slide 3: Highlights for Q1 2017
Highlights for Q1 2017 Tromsø • Solid quarter sales of NOK 18.2 mill (NOK 17.3 mill) • Slightly weaker EBITDA NOK -4.1 mill (NOK -3.6 mill) • Q1 Woulgan® sales NOK 0.4 mill • ArcticZymes sales of NOK 8.9 mill 10% above the strong Q1 2016 3
Slide 4: Q1 Financials
Q1 Financials ites. BIOTEC ret” PHARMACON
Slide 5: Financial highlights Q1 2017
Financial highlights Q1 2017 NOK million Q1 2017 Q1 2016 3M 2017 3M 2016 Sales Enzymes 8.9 8.1 8.9 8.1 Sales BetaGlucans 9.3 9.2 9.3 9.2 Other revenues 1.6 1.9 1.6 1.9 Total revenues 19.8 19.2 19.8 19.2 Enzymes 2.6 2.6 2.6 2.6 BetaGlucans -4.6 -4.2 -4.6 -4.2 Corporate unallocated -2.1 -1.9 -2.1 -1.9
Slide 6: Cash flow and cash position
Cash flow and cash position NOK million Q1 2017 Q1 2016 3M 2017 3M 2016 Operating activities -9.8 -10.7 -9.8 -10.7 Investing activities -1.4 0 -1.4 0 Financing activities 0 0 0 0 Changes in cash and cash equivalent -11.2 -10.7 -11.2 -10.7 Cash and cash equivalents at the 57.7 78.3 57.7 78.3 beginnin
Slide 7: Beta-glucans
BIOTEC °° PHARMACON
Slide 8: Beta-glucans – segment numbers
Beta-glucans – segment numbers NOK million Q1 2017 Q1 2016 3M 2017 3M 2016 Sales Animal & Consumer Health 8.9 9.2 8.9 9.2 Sales Woulgan 0.4 0 0.4 0 Other revenues 0.7 0.5 0.7 0.5 Total revenues 10.0 9.7 10.0 9.7 Cost of Goods -5.9 -4.1 -5.9 -4.1 Personnel expenses -5.7 -5.6 -5.7 -5.6 Operating expen
Slide 9: Activities outside Woulgan®
Activities outside Woulgan® • Good sales in animal health products continues • A number of commercial activities within consumer health generating leads and opportunities for the M-Gard® product • About 120 patients treated with the vaccine/SBG combination at Memorial Sloan Kettering Cancer Center -
Slide 10: Woulgan® Positioning & Highlights
Woulgan® Positioning & Highlights Substantial potential: ability to kick-start “stalled wounds” Highlights Woulgan positioned for stalled wounds not closed by 40% • Repeating Woulgan Gel sales after 4 weeks of standard care Market Access • Positive experiences lead to continued use -Tenders, Reimbur
Slide 11: Highlights Germany
Highlights Germany • More Homecare companies evaluating Woulgan® • Prepared sales campaign targeting high wound care prescribers in GP channel • VLU case series recruiting & expert opinion progressing • Bundestag refined definition of “dressing” for reimbursement • Sick funds continuing to pay for W
Slide 12: Highlights UK
Highlights UK •Replied to further questions on health economic analysis from Drug Tariff at the end of February •First orders via NHS supply chain (outside of Drug Tariff) • Building sales pipeline-creating sales leads •UK case series published in Journal of Wound Care (JoWC) in Feb. •Woulgan articl
Slide 13: Highlights Nordics
Highlights Nordics •2017 targeting 30% tender access •Most sales in Finland so far •Running many evaluations at county level in all countries •Active at wound congresses (Sweden, Finland and Norway) • Recruitment to the Nordic evaluation series started. Promising results so far. 13
Slide 14: Highlights Central Marketing
Highlights Central Marketing Brand building • Exhibiting at EWMA (May) – Europe's largest WC conference • 3 publications • 2 KOL webinars- Germany & UK • Regular posting & content (Facebook, Twitter & Blog) Sales leads • Campaigns- Facebook (testimonials), Google Ads for EWMA & wound specialists E-b
Slide 15: US opportunity and PMCF study
US opportunity and PMCF study US opportunity • FDA confirmed Woulgan Gel as class 1 exempt • Likely 1st step towards a higher classification and reimbursement later • Developing U.S. strategy and in parallel seeking U.S. partner for strategic alliance PMCF (post market clinical follow up): • Adding
Slide 16: Business Development – other areas
Business Development – other areas • Dutch evaluation on track for summer reimbursement application • Australia regulatory application in progress • Canada registration analysis complete 16
Slide 17: ArcticZymes
ArcticZymes Molecular research and diagnostics
Slide 18: Enzymes – segment numbers
Enzymes – segment numbers NOK million Q1 2017 Q1 2016 3M 2017 3M 2016 Sales enzymes 8.9 8.1 8.9 8.1 Other revenues 0.9 1.4 0.9 1.4 Total revenues 9.8 9.5 9.8 9.5 Cost of goods 0.3 -0.2 0.3 -0.2 Personnel expenses -5.4 -5.2 -5.4 -5.2 Operating expenses -2.1 -1.6 -2.1 -1.6 EBITDA 2.6 2.6 2.6 2.6 Depre
Slide 19: Commercial Update
Commercial Update Recently Launched Product Updates • Heat-Labile Exonuclease I (HL-ExoI) • Launched in Q4 • Complements our Shrimp Alkaline Phosphatase portfolio • 1st customer has already integrated enzyme into their sequencing kits • Interest for use in Sanger and Next Generation Sequencing (NGS)
Slide 20: Commercial Update
Commercial Update New Product Developments: SAN Portfolio • Continued growing interest in SAN for use in bio-manufacturing (e.g. production of viruses for utility in gene therapy) • ArcticZymes will fast track 2 new product developments for 2017 launch to serve immediate commercial demands + = SAN B
Slide 21: Outlook 2017
Outlook 2017 ‘ah - o@ete. BIOTEC ret” PHARMACON
Slide 22: Outlook 2017
Outlook 2017 • Woulgan: Drive commercial traction in core markets including favorable reimbursement in UK • Retain position in the Animal Health market with a modest growth • Build commercial platform in Consumer Health • Launch further products in ArcticZymes including Polymerases • Continue to wid
Slide 23: Contact
Contact: Barge Sgrvoll bso@biotec.no TIf: 95290187 www.biotec.no
ArcticZymes Technologies — Q1 2017 Earnings Presentation on 6ix